On Demand Education
IDgenetix simplifies the concept of pharmacogenomics and its relevance to mental health.
Incorporating DecisionDx-Melanoma into Clinical Practice: Molecular Information for Personalized Management Decisions
Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients with Barrett’s Esophagus
Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Non-Dysplastic Barrett’s Esophagus: A Spatial-Temporal Analysis
Gene Expression Profiling: A Diagnostic Ancillary Test To Aid In The Diagnosis Of Melanocytic Lesions
Utility of GEP in Difficult to Diagnose Melanocytic Lesions
Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies
Barrett’s Esophagus Panel: Predicting Progression in Barrett’s Esophagus Recent Advances Webinar
Risk Stratification and Management of Dysplastic Barrett’s Esophagus
TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*
Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).